Preview

Вестник трансплантологии и искусственных органов

Расширенный поиск

ЛЕЧЕНИЕ ГЕПАТИТА C БЕЗ ИСПОЛЬЗОВАНИЯ ПРЕПАРАТОВ ИНТЕРФЕРОНА У БОЛЬНЫХ, ПЕРЕНЕСШИХ ТРАНСПЛАНТАЦИЮ ПЕЧЕНИ

https://doi.org/10.15825/1995-1191-2015-3-83-88

Полный текст:

Аннотация

В обзоре представлен анализ текущего состояния проблемы противовирусной терапии хронического гепатита С у пациентов, перенесших трансплантацию печени. В работе рассматриваются основные ограничения, связанные с применением существующих на рынке препаратов, и предпосылки к внедрению новых схем, не содержащих интерферона. Представлен обзор опубликованных к настоящему времени исследований, посвященных применению препаратов прямого противовирусного действия с основными результатами и выводами

Об авторах

М. Ш. Хубутия
ГБУЗ «Научно-исследовательский институт скорой помощи им. Н.В. Склифосовского», Москва, Российская Федерация
Россия


В. Е. Сюткин
ГБУЗ «Научно-исследовательский институт скорой помощи им. Н.В. Склифосовского», Москва, Российская Федерация
Россия

129010, г. Москва, Б. Сухаревская пл., д. 3, корп. 9. Тел. (903) 127-94-78.



Список литературы

1. Scientifi c Registry of Transplant Recipients 2012 annual data report. Rockville, MD: Health Resources and Services Administration. 2012; Available from: http:// srtr.transplant.hrsa.gov/annual_reports/2012/pdf/03_liver_13.pdf.

2. World Health Organ ization, Spanish National Transplant Organization. Global observatory on donation and transplantation.2012; Available from: http://issuu.com/o-n-t/docs/2012ad.

3. Berenguer M, Ferre ll L, Watson J et al. HCV-related fi brosis progression following liver transplantation: increase in recent years. J Hepatol. 2000; 32 (4): 673–684.

4. Prieto M, Berenguer M, Rayon JM et al. High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: relationship with rejection episodes. Hepatology. 1999; 29 (1): 250–256.

5. Narang TK, Ahrens W, Russo MW. Post-liver transplant cholestatic hepatitis C: a systematic review of clinical and pathological fi ndings and application of consensus criteria. Liver Transpl. 2010; 16 (11): 1228–1235.

6. Crespo G, Marino Z, N avasa M et al. Viral hepatitis in liver transplantation. Gastroenterology. 2012; 142 (6):1373–1383 e1371.

7. Terrault NA and Bereng uer M. Treating hepatitis C infection in liver transplant recipients. Liver Transpl.2006; 12 (8): 1192–1204.

8. Levitsky J, Fiel MI, No rvell JP et al. Risk for immunemediated graft dysfunction in liver transplant recipients with recurrent HCV infection treated with pegylated interferon. Gastroenterology. 2012; 142 (5): 1132–1139 e1131.

9. Berenguer M, Palau A, Ag uilera V et al. Clinical benefi ts of antiviral therapy in patients with recurrent hepatitis C following liver transplantation. Am J Transplant. 2008;8 (3): 679–687.

10. Gurusamy Ks TE, Xiroucha kis E, Burroughs Ak, Davidson Br. Antiviral therapy for recurrent liver graft infection with hepatitis C virus (Review). 2010.

11. Selzner N, Guindi M, Ren ner EL et al. Immune-mediated complications of the graft in interferon-treated hepatitis C positive liver transplant recipients. J Hepatol. 2011; 55 (1): 207–217.

12. Coilly A, Roche B, Dumort ier J et al. Safety and effi cacy of protease inhibitors to treat hepatitis C after liver transplantation: a multicenter experience. J Hepatol. 2014; 60 (1): 78–86.

13. Pungpapong S, Aqel BA, Kon ing L et al. Multicenter experience using telaprevir or boceprevir with peginterferon and ribavirin to treat hepatitis C genotype 1 after liver transplantation. Liver Transpl. 2013; 19 (7): 690–700.

14. Burton JRJr, O'leary JG, Ve rna EC et al. A US multicenter study of hepatitis C treatment of liver transplant recipients with protease-inhibitor triple therapy. J Hepatol. 2014; 61 (3): 508–514.

15. Saab S, Manne V, Bau S et al . Boceprevir in liver transplant recipients. Liver Int. 2014.

16. Gentile I, Borgia F, Buonomo AR et al. ABT-450: a novel protease inhibitor for the treatment of hepatitis C virus infection. Current medicinal chemistry. 2014; 21 (28): 3261–3270.

17. Feld JJ, Kowdley KV, Coakley E et al. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med. 2014; 370 (17): 1594–1603.

18. Zeuzem S, Jacobson IM, Baykal T et al. Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med. 2014; 370 (17): 1604–1614.

19. Ferenci P, Bernstein D, Lalezar i J et al. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med. 2014; 370 (21): 1983–1992.

20. Andreone P, Colombo MG, Enejosa JV et al. ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection. Gastroenterology. 2014; 147 (2):359–365 e351.

21. Poordad F, Hezode C, Trinh R et a l. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med. 2014; 370 (21): 1973–1982.

22. Samuel D, Charlton M, Gane E et al . Sofosbuvir and ribavirin for the treatment of recurrent hepatitis C infection after liver transplantation: results of a prospective, multicenter Study. J Hepatol. 2014; 60 (Suppl.): S26.

23. Reddy K, Everson GT, Flamm SL et a l. Ledipasvir/Sofosbuvir with Ribavirin for the Treatment of HCV in Patients with Post Transplant Recurrence: Preliminary Results of a Prospective, Multicenter Study. Program and abstracts of the 65th Annual Meeting of the American Association for the Study of Liver Diseases. Boston, Massachusetts, 2014; 8.

24. Brown RS, Reddy K, O'leary JG et a l. Safety and Effi cacy of New DAA-based Therapy for Hepatitis C Post-Transplant: Interval Results from the HCV-TARGET Longitudinal, Observational Study. Program and abstracts of the 65th Annual Meeting of the American Association for the Study of Liver Diseases. Boston, Massachusetts, 2014; LB-4.

25. Levin RBJ. Safety and Effi cacy of New DAA-based Therapy for Hepatitis C Post-Transplant: Interval Results from the HCV-TARGET Longitudinal, Observational Study. 65th Annual Meeting of the American Association for the Study of Liver Diseases, Boston, Massachusetts,2014; Available from: http://www.natap.org/2014/ AASLD/AASLD_19.htm.

26. Kwo PY, Mantry PS, Coakley E et al . An Interferon-free Antiviral Regimen for HCV after Liver Transplantation. N Engl J Med. 2014; 371 (25): 2375–2382.


Для цитирования:


Хубутия М.Ш., Сюткин В.Е. ЛЕЧЕНИЕ ГЕПАТИТА C БЕЗ ИСПОЛЬЗОВАНИЯ ПРЕПАРАТОВ ИНТЕРФЕРОНА У БОЛЬНЫХ, ПЕРЕНЕСШИХ ТРАНСПЛАНТАЦИЮ ПЕЧЕНИ. Вестник трансплантологии и искусственных органов. 2015;17(3):83-88. https://doi.org/10.15825/1995-1191-2015-3-83-88

For citation:


Khubutia M.S., Syutkin V.E. TREATMENT OF HEPATITIS C WITHOUT INTERFERON IN PATIENTS UNDERGOING LIVER TRANSPLANTATION. Russian Journal of Transplantology and Artificial Organs. 2015;17(3):83-88. (In Russ.) https://doi.org/10.15825/1995-1191-2015-3-83-88

Просмотров: 593


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1995-1191 (Print)
ISSN 2412-6160 (Online)